China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2014 - KiiiTV.com South Texas, Corpus Christi, Coastal Bend

China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2014

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE China Cord Blood Corporation

4Q14 Added 17,136 New Subscribers

4Q14 Revenue Increased to RMB151.9 Million

4Q14 Gross Profit Up 17.4% YOY to RMB124.6 Million

Conference Call to be Held on June 19, 2014 at 8:00 a.m. ET

HONG KONG, June 18, 2014 /PRNewswire/ -- China Cord Blood Corporation (NYSE: CO) ("CCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced its preliminary unaudited financial results for the fourth quarter and 2014 fiscal year ended March 31, 2014.

Fiscal 2014 Fourth Quarter Highlights

  • Revenues for the fourth quarter of fiscal 2014 increased to RMB151.9 million ($24.4 million) from RMB133.0 million in the prior year period.  
  • New subscriber sign-ups and accumulated subscriber base reached 17,136 and 376,623, respectively.  
  • Gross profit increased to RMB124.6 million ($20.0 million) from RMB106.1 million in the prior year period.  
  • Operating income amounted to RMB64.0 million ($10.3 million), up from RMB50.7 million in the prior year period.
  • Interest expense decreased to RMB17.0 million ($2.7 million), compared to RMB22.1 million in the prior year period, due to interest expense capitalization.
  • Net income attributable to the Company's shareholders was RMB39.5 million ($6.4 million), compared to RMB23.0 million in the prior year period.
  • Operating cash flow for the quarter was RMB137.4 million ($22.1 million).

Fiscal 2014 Full Year Highlights

  • Revenues for the full year of fiscal 2014 increased to RMB572.9 million ($92.2 million) from RMB526.1 million in the prior year.
  • New subscriber sign-ups reached 64,641 and accumulated subscriber base expanded to 376,623.
  • Gross profit increased 11.2% year-over-year to RMB466.6 million ($75.1 million).
  • Operating income increased 10.8% year-over-year to RMB231.9 million ($37.3 million).
  • Interest expense was RMB70.1 million ($11.3 million), similar to the prior year.
  • Net income attributable to the Company's shareholders increased 17.3% to RMB131.9 million ($21.2 million), up from RMB112.4 million in the prior year.
  • Operating cash flow for the full year of fiscal 2014 was RMB536.0 million ($86.2 million).

"Although fiscal 2014 was heavily affected by the drop in the number of newborns following the Dragon year, our team's dedicated effort resulted in more than 17,000 new subscribers in the fourth quarter," stated Ms. Ting Zheng, Chief Executive Officer of China Cord Blood Corporation.

"The geographical breakdown and payment mix of our new subscribers in the fourth quarter were comparable to previous quarters, resulting in a consistent level of cash flow. We continue to focus on sales and service efficiency to strengthen our market reputation. Heading into fiscal 2015, as our new facilities in Guangdong and Zhejiang become operational, we expect to increase our penetration in these regions, deepen our market reach and expand our overall leadership position in China's cord blood banking industry."

Fourth Quarter and Full Year Summary Ended March 31, 2013 and 2014


Three Months Ended
March 31,


Year Ended
March 31,


2013


2014


2013


2014

(in thousands)

RMB


RMB

US$


RMB


RMB

US$

Revenues

133,011


151,915

24,438


526,123


572,857

92,152

Gross Profit

106,104


124,574

20,040


419,502


466,632

75,064

Operating Income

50,747


64,013

10,298


209,314


231,926

37,308

Net Income Attributable to the
    Company's Shareholders

23,028


39,539

6,361


112,447


131,903

21,218

Earnings per Ordinary Share
 – Basic[1] and Diluted(RMB/US$)

0.32


0.46

0.07


1.49


1.60

0.26











Revenue Breakdown (%)










Processing Fees

72.2%


71.1%



75.4%


70.9%


Storage Fees

27.8%


28.9%



24.6%


29.1%












New Subscribers (persons)

16,059


17,136



72,228


64,641


Total Accumulated Subscribers
    (persons)

311,982


376,623



311,982


376,623












[1] The terms of the convertible notes issued to KKR China Healthcare Investment Limited ("KKR") and Golden Meditech Holdings Limited ("Golden Meditech") provide each party with the ability to participate in any excess cash dividend. Therefore, the calculation of basic EPS has taken into consideration the effect of such participating rights of RMB0.08 ($0.01) and RMB0.21 ($0.03) for the three months and year ended March 31, 2014, respectively.

Summary – Selected Cash Flow Statement Items


Three Months Ended


Year Ended


March 31, 2014


March 31, 2014

(in thousands)

RMB

US$


RMB

US$

Net cash provided by operating activities

137,399

22,103


536,015

86,226

Net cash used in investing activities

(9,037)

(1,454)


(149,883)

(24,111)

Net cash provided by financing activities

-

-


2,336

376

Fourth Quarter of Fiscal 2014 Financial Results

REVENUES. Revenues increased 14.2% to RMB151.9 million ($24.4 million) in the fourth quarter of fiscal 2014 from RMB133.0 million in the prior year period, driven mainly by increased pricing implemented since April 2013, the addition of new subscribers, and the increased contribution of storage revenue from the Company's expanded accumulated subscriber base.

Revenues generated from storage fees increased to RMB44.0 million ($7.1 million), up from RMB37.0 million in the prior year period. As a result of the expanded subscriber base, revenue from storage fees, as a percentage of total revenue, increased to 28.9%.

Revenues generated from processing fees in the fourth quarter were RMB107.9 million ($17.3 million), up from RMB96.0 million in the prior year period due to higher pricing and an increase of new subscribers. 17,136 new subscribers were recorded during the fourth quarter of fiscal 2014, representing a 6.7% year-over-year increase. Revenues generated from processing fees accounted for 71.1% of total revenues, compared to 72.2% in the prior year period.

GROSS PROFIT. Gross profit for the fourth quarter of fiscal 2014 amounted to RMB124.6 million ($20.0 million) from RMB106.1 million in the prior year period. Gross margin stood at 82.0%, as the Company benefitted from increased storage revenue as a percent of the overall revenue and from economies of scale.

OPERATING INCOME. Operating income for the fourth quarter was RMB64.0 million ($10.3 million), compared to RMB50.7 million in the prior year period. Operating margin increased to 42.1% from 38.2% in the prior year period. The increase was mainly due to higher gross profit, offset in part by an increase in operating expenses. Depreciation and amortization expenses for the fourth quarter were RMB9.8 million ($1.6 million).

Research and Development Expenses. Research and development expenses amounted to RMB2.5 million ($0.4 million).

Sales and Marketing Expenses. Sales and marketing expenses for the fourth quarter amounted to RMB28.4 million ($4.6 million), compared to RMB26.1 million in the prior year period. The increase in sales and marketing expenses is in-line with the overall increase in sales activities. But as a percentage of revenue, 2014 fourth quarter sales and marketing expenses decreased to 18.7% from 19.6% in the prior year period, and remained the same as the third quarter of fiscal 2014.

General and Administrative Expenses. General and administrative expenses increased modestly to RMB29.6 million ($4.8 million), from RMB27.0 million in the prior year period. However as a percentage of revenue, general and administrative expenses were 19.5%, down from 20.3% in the prior year period.

OTHER INCOME AND EXPENSES

Interest Expense. Interest expense decreased to RMB17.0 million ($2.7 million) from RMB22.1 million in the prior year period. The decrease was largely attributable to the increase in the capitalization of interest expense for the Company's construction of new facilities. Interest expense capitalized in the fourth quarter of fiscal 2014 amounted to RMB7.0 million ($1.1 million), compared to RMB1.3 million in the prior year period.

NET INCOME ATTRIBUTABLE TO THE COMPANY'S SHAREHOLDERS. Due primarily to the increase in operating income and the reduction in interest expense, net income attributable to the Company's shareholders for the fourth quarter of fiscal 2014 increased to RMB39.5 million ($6.4 million) from RMB23.0 million in the prior year period. Net margin for the fourth quarter of fiscal 2014 stood at 26.0%.

EARNINGS PER SHARE. The terms of the convertible notes issued to KKR and Golden Meditech provide each party with the ability to participate in any Excess Cash Dividend[2]. Therefore, the calculation of basic and diluted EPS incorporates the effect of such participating rights of RMB0.08 ($0.01). Basic and diluted earnings per ordinary share for the fourth quarter of fiscal 2014 were RMB0.46 ($0.07).

LIQUIDITY. As of March 31, 2014, the Company had cash and cash equivalents of RMB1,882.9 million ($302.9 million) compared to RMB1,494.1 million as of March 31, 2013. The Company had total debt of RMB837.8 million ($134.8 million) as of March 31, 2014. Operating cash flow for the quarter amounted to RMB137.4 million ($22.1 million).

[2]  

"Excess Cash Dividend" means any cash dividend to holders of shares that, together with all other cash dividends previously paid to holders of shares in the same financial year, exceeds, on a per share basis, an amount equal to the interest that has accrued and shall accrue at 7% in such financial year divided by the number of shares into which the note is convertible at the conversion price then in effect on the relevant record date.

Full Year Fiscal 2014 Financial Results

For the 2014 fiscal year, total revenues increased 8.9% to RMB572.9 million ($92.2 million) from RMB526.1 million in the prior year. The increase was largely attributable to the implementation of higher service fees and the expansion of the Company's accumulated subscriber base to 376,623 subscribers, which outweighed the impact of the decrease in new subscriber numbers after the Dragon year. Revenues from processing fees increased slightly by 2.4% but storage fees grew by 28.7%. Gross profit increased 11.2% to RMB466.6 million ($75.1 million) from RMB419.5 million in the prior year. Operating income increased  10.8% to RMB231.9 million ($37.3 million) from RMB209.3 million in the prior year. Net income attributable to the Company's shareholders totaled RMB131.9 million ($21.2 million). Basic and diluted earnings per share attributable to ordinary shares were RMB1.60 ($0.26). Net cash provided by operating activities for the full year of fiscal 2014 was RMB536.0 million ($86.2 million), compared to RMB578.6 million in fiscal 2013.

Conference Call

The Company will host a conference call at 8:00 a.m. ET on Thursday, June 19, 2014 to discuss its financial performance and give a brief overview of the Company's recent developments, followed by a question and answer session. Interested parties may access the audio webcast through the Company's IR website at http://ir.chinacordbloodcorp.com. A replay of the webcast will be accessible two hours after the conference call and available for three weeks at the same URL link above. Listeners may also access the call by dialing 1-631-514-2526 or 1-855-298-3404 for US callers or +852-5808-3202 for Hong Kong callers, access code: 1106709.

About China Cord Blood Corporation

China Cord Blood Corporation is the first and largest umbilical cord blood banking operator in China in terms of geographical coverage and the only cord blood banking operator with multiple licenses. Under current PRC government regulations, only one licensed cord blood banking operator is permitted to operate in each licensed region and only seven licenses have been authorized as of today. China Cord Blood Corporation provides cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services. For more information, please visit our website at http://www.chinacordbloodcorp.com.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. These statements relate to future events or the Company's future financial performance. The Company has attempted to identify forward-looking statements by terminology including "anticipates", "believes", "expects", "can", "continue", "could", "estimates", "intends", "may", "plans", "potential", "predict", "should" or "will" or the negative of these terms or other comparable terminology. These statements are only predictions, uncertainties and other factors may cause the Company's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. The information in this press release is not intended to project future performance of the Company. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company does not guarantee future results, levels of activity, performance or achievements. The Company expectations are as of the date this press release is issued, and the Company does not intend to update any of the forward-looking statements after the date this press release is issued to confirm these statements to actual results, unless required by law.

The forward-looking statements included in this press release are subject to risks, uncertainties and assumptions about the Company's businesses and business environments. These statements reflect the Company's current views with respect to future events and are not a guarantee of future performance. Actual results of the Company's operations may differ materially from information contained in the forward-looking statements as a result of risk factors some of which include, among other things: continued compliance with government regulations regarding cord blood banking in the People's Republic of China, or PRC and any other jurisdiction in which the Company conducts its operations; changing legislation or regulatory environments (including the recent revision on One Child Policy) in the PRC and any other jurisdiction in which the Company conducts its operations; the acceptance by subscribers of the Company's different pricing and payment options and reaction to the introduction of the Company's premium-quality pricing strategy; demographic trends in the regions of the PRC in which the Company is the exclusive licensed cord blood banking operator; labor and personnel relations; the existence of a significant shareholder able to influence and direct the corporate policies of the Company; credit risks affecting the Company's revenue and profitability; changes in the healthcare industry, including those which may result in the use of stem cell therapies becoming redundant or obsolete; the Company's ability to effectively manage its growth, including implementing effective controls and procedures and attracting and retaining key management and personnel; changing interpretations of generally accepted accounting principles; the availability of capital resources, including in the form of capital markets financing opportunities, in light of industry developments affecting issuers that have pursued a "reverse merger" with an operating company based in China, as well as general economic conditions; compliance with restrictive debt covenants under our senior convertible notes; and other relevant risks detailed in the Company's filings with the Securities and Exchange Commission in the United States.

This announcement contains translations of certain Renminbi amounts into U.S. dollars at specified rates solely for the convenience of readers. Unless otherwise noted, all translations from Renminbi to U.S. dollars as of and for the periods ending March 31, 2014 were made at the noon buying rate of RMB6.2164 to $1.00 on March 31, 2014 in the City of New York for cable transfers in Renminbi per U.S. dollar as certified for customs purposes by the Federal Reserve Bank of New York. China Cord Blood Corporation makes no representation that the Renminbi or U.S. dollar amounts referred to in this press release could have been or could be converted into U.S. dollars or Renminbi, at any particular rate or at all.

For more information, please contact:

China Cord Blood Corporation
Investor Relations Department
Tel: (+852) 3605-8180
Email: ir@chinacordbloodcorp.com 

ICR, Inc.
Mr. William Zima
Tel: (+86) 10-6583-7511
U.S. Tel: (646) 405-5185
Email: William.zima@icrinc.com

CHINA CORD BLOOD CORPORATION

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

As of March 31, 2013 and 2014








March 31,


March 31,


2013


2014


RMB


RMB


US$


(in thousands except share data)







ASSETS






Current assets






Cash and cash equivalents

1,494,099


1,882,901


302,892

Accounts receivable, less allowance for doubtful accounts






(March 31, 2013: RMB14,112; March 31, 2014: RMB20,322)

73,076


95,273


15,326

Inventories

10,265


31,583


5,080

Prepaid expenses and other receivables

11,602


37,010


5,954

Debt issuance costs

3,678


3,616


582

Deferred tax assets

5,454


7,664


1,233

Total current assets

1,598,174


2,058,047


331,067

Property, plant and equipment, net

468,272


626,632


100,804

Non-current prepayments

212,633


208,894


33,604

Non-current accounts receivable, less allowance for doubtful accounts






(March 31, 2013: RMB36,361; March 31, 2014: RMB42,703)

249,370


225,496


36,275

Inventories

39,730


48,385


7,783

Intangible assets, net

125,170


120,549


19,392

Available-for-sale equity securities

88,404


144,247


23,204

Other investment

189,129


189,129


30,424

Debt issuance costs

11,667


7,854


1,263

Deferred tax assets

3,727


1,789


288

Total assets

2,986,276


3,631,022


584,104







LIABILITIES






Current liabilities






Bank loan

50,000


60,000


9,652

Accounts payable

9,890


10,422


1,677

Accrued expenses and other payables

84,006


102,559


16,498

Deferred revenue

172,328


196,432


31,599

Amounts due to related parties

11,241


21,453


3,452

Income tax payable

4,983


2,571


414

Deferred tax liabilities

-


3,900


627

Total current liabilities

332,448


397,337


63,919

Convertible notes

751,781


777,753


125,113

Non-current deferred revenue

530,258


823,921


132,540

Other non-current liabilities

107,158


164,077


26,395

Deferred tax liabilities

23,168


27,938


4,494

Total liabilities

1,744,813


2,191,026


352,461







EQUITY






Shareholders' equity of China Cord Blood Corporation






Ordinary shares






- US$0.0001 par value, 250,000,000 shares authorized,






73,140,147 shares issued and 73,003,248 shares outstanding






as of March 31, 2013 and 2014, respectively

50


50


8

Additional paid-in capital

798,221


798,221


128,405

Treasury stock, at cost






(March 31, 2013 and 2014: 136,899 shares, respectively)

(2,815)


(2,815)


(453)

Accumulated other comprehensive income

18,256


84,263


13,555

Retained earnings

423,420


555,323


89,331

Total equity attributable to China Cord Blood Corporation

1,237,132


1,435,042


230,846

Non-controlling interests

4,331


4,954


797

Total equity

1,241,463


1,439,996


231,643

Total liabilities and equity

2,986,276


3,631,022


584,104













 

 

 

CHINA CORD BLOOD CORPORATION

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

For the Three Months and Year ended March 31, 2013 and 2014














Three months ended March 31,


Year ended March 31,


2013


2014


2013


2014


RMB


RMB


US$


RMB


RMB


US$


(in thousands except share data)













Revenues

133,011


151,915


24,438


526,123


572,857


92,152

Direct costs

(26,907)


(27,341)


(4,398)


(106,621)


(106,225)


(17,088)

Gross profit

106,104


124,574


20,040


419,502


466,632


75,064

Operating expenses












Research and development

(2,249)


(2,539)


(408)


(8,459)


(9,773)


(1,572)

Sales and marketing

(26,116)


(28,415)


(4,571)


(93,684)


(112,689)


(18,128)

General and administrative

(26,992)


(29,607)


(4,763)


(108,045)


(112,244)


(18,056)

Total operating expenses

(55,357)


(60,561)


(9,742)


(210,188)


(234,706)


(37,756)

Operating income

50,747


64,013


10,298


209,314


231,926


37,308

Other expense, net












Interest income

4,002


4,615


742


15,064


16,870


2,714

Interest expense

(22,070)


(16,990)


(2,733)


(70,097)


(70,075)


(11,273)

Exchange (loss)/gain

(25)


329


53


(984)


80


13

Dividend income

-


-


-


4,685


9,911


1,594

Others

924


565


91


203


2,212


356

Total other expense, net

(17,169)


(11,481)


(1,847)


(51,129)


(41,002)


(6,596)

Income before income tax

33,578


52,532


8,451


158,185


190,924


30,712

Income tax expense

(10,483)


(12,830)


(2,064)


(38,543)


(58,398)


(9,394)

Net income

23,095


39,702


6,387


119,642


132,526


21,318

Net income attributable to non-controlling interests

(67)


(163)


(26)


(7,195)


(623)


(100)

Net income attributable to China
Cord Blood Corporation's shareholders

23,028


39,539


6,361


112,447


131,903


21,218













Net income per share:












Attributable to ordinary shares












- Basic

0.32


0.46


0.07


1.49


1.60


0.26

- Diluted

0.32


0.46


0.07


1.49


1.60


0.26













Other comprehensive income












- Net effect of foreign currency
   translation, net of nil tax

2,936


(3,686)


(593)


1,296


8,299


1,335

- Net unrealized gain/(loss) in
   available-for-sale equity securities,
   net of nil tax

12,023


(6,346)


(1,021)


(9,120)


57,708


9,283

Comprehensive income

38,054


29,670


4,773


111,818


198,533


31,936













Comprehensive income attributable
   to non-controlling interests

(67)


(163)


(26)


(7,172)


(623)


(100)

Comprehensive income
   attributable to China Cord Blood
Corporation's shareholders

37,987


29,507


4,747


104,646


197,910


31,836













©2012 PR Newswire. All Rights Reserved.